Forticell Bioscience Inc fka FORBQ

[sidedraft]

FORBQ: SEC revoked:

http://www.sec.gov/litigation/admin/2013/34-69664.pdf

[Renee]

FORBQ SEC Suspension:

http://www.sec.gov/litigation/suspensions/2013/34-69532.pdf

ORDER:

http://www.sec.gov/litigation/suspensions/2013/34-69532-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2013/34-69533.pdf

[MsCoffeenut333]

Congrats!


Hope you grabbed some of your $$ on this one!


Great Risk/Reward Here :)

[Josh_Ortiz]

Can somebody please explain to me why this stock rose so high today if the volume is only at 1,000.

[geneanddean]

it's a good question. i think somethingis possible, but i don't know anything and i don't know if the shares would be cancelled even if there was one. i just hope someone hits the offer, lol.

[jeffn]

Why?

[geneanddean]

Bought more at .002.

[greenbayslacker]

she's dropping today...

I wonder if they announced share cancelation or what?


Might be a great buy opp some time today...

Right now the bid/ ask is .0121/.07......... very volitile.

[TARKA]

No discussions, for over a year!

[TARKA]

Where is everybody?

I want your opinions!!

[realtorNH]

looking great from where I am sitting

[aquaspin]

Looks like this might start trending higher untill we get more news.

[aquaspin]

I agree that we are at the crossroads. I think we will get a 5+ bagger here since we didn't get rejection news. If it gets approved in the future then I think we will be trading in dollars per share again. Who knows for sure if it will get approved though.

[realtorNH]

We are at an exciting crossroads for sure. I think the recent "news" will breath life/hope into FORB. If we can get a little more volume I think a 5 bagger is not out of the question in the short term. Chart looks fine from where I am sitting.

[aquaspin]

I'm still in with 33k shares. If the company can come up with enough money to continue tests to get FDA approval then this will be trading in the dollars per share again IMO.

[J-RO]

Made a nice move today, whose in?

[MWM]

Rebounding .05 X .055

[aquaspin]

FORB is a runnin...

[aquaspin]

I knew the response wouldn't be all that bad! I still think I will make a lot of money on this one...just a matter of time!

[realtorNH]

FORB Forticell Bioscience Gets FDA Formal Response For Orcel

Apr 25, 2008 12:00:38 (ET)


(MORE TO FOLLOW) Dow Jones Newswires

April 25, 2008 12:00 ET (16:00 GMT)

[MWM]

Interesting 8K here...

Item 8.01 Other Events



On April 24, 2008, we received a formal response from the FDA to our application for pre-market approval to sell ORCEL for the treatment of venous leg ulcers. The FDA’s extensive and detailed letter asked for clarification on a variety of safety, efficacy and statistical issues, and questioned the handling of various aspects of the clinical data. FDA also suggested remedies for the deficiencies that they noted. Provided management can remedy the concerns of the FDA, there seems to exist the possibility of a future approval.


Currently, we do not have the funds that we believe are needed to address the comments in the FDA’s letter. We are considering our various alternatives.

[J-RO]

FORB Chart ~ I've seen prettier, but may be good for a bounce, eventually, lol

[OTC BB King]

Agree.

[J-RO]

Trading like she wants to bounce....

[mkinhaw]

Yeah sounds right
MK

[MWM]

even as a shell it might be worth more than .04... but if they announce BK or something it could really tank...

[mkinhaw]

Thx, I ll keep on watch too
MK

[MWM]

Yep I'm reading a little closer right now, I'm gonna jump back out, did not do enough DD here...

The 10K spells it out pretty clear that they only have enough funding let til march...

I'll keep her on watch though...

[mkinhaw]

Did you read all the latest
filings ?
Seems a lot of paper coming plus right now they laid off almost everyone
because of the non approve from FDA
thoughts ?
thx
MK

[MWM]

About the company

Advancing Regenerative Medicine Through Development of Cellular Technology and Advanced Biomaterial Products
Forticell, (formerly Ortec International, Inc.), founded in 1991, was formed to commercialize the technology developed by Dr. Mark Eisenberg, an Australian general practitioner, to treat his son for the affects of a rare genetic disease, Epidermolysis Bullosa (EB). In a desperate attempt to save his son from having to undergo additional surgeries, Dr. Eisenberg discovered that he could create a substitute skin using cells from infant foreskins and delivering these in a collagen matrix. In 1987, Dr. Eisenberg successfully applied the technology he discovered, now known as OrCel®, on his son.

Today, Forticell Bioscience, Inc. (FORB.OB) has evolved into a fully integrated organization experienced in the development of natural biomaterials and tissue engineered cellular therapies. Forticell completed its initial public offering in January 1996 and is headquartered in Columbia University’s Audubon Biomedical Science and Technology Park, located in New York City, New York.

Forticell is a company focused on advancing regenerative medicine and stem cell therapy through the development and commercialization of innovative products by combining advanced cell technology and advanced biomaterials. Forticell’s lead product is OrCel® (Bilayered Cellular Matrix). Forticell’s current focus is the application of OrCel® to heal chronic and acute wounds. OrCel® is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair.

A pivotal clinical trial evaluating a cryopreserved version of OrCel® in the treatment of venous leg ulcers has been completed and a Pre Market Approval (PMA) application has been filed. Forticell has already obtained FDA approvals for use of a non-frozen version of OrCel® in the treatment of Epidermolysis Bullosa and donor sites in burn patients. In addition, the FDA has granted Forticell approval to initiate a pivotal (Phase III) trial evaluating OrCel® for the treatment of diabetic foot ulcers.

Forticell recently acquired two fibrin derived advanced biomaterial technologies, Fibrin Microbeads (Fibrin MB) and Haptides™. Fibrin MB have the potential to play a significant role in advancing stem cell therapy having demonstrated the ability to efficiently recover adult stem cells and allow for their growth, proliferation, and potential reimplantation into the patient. Haptides™ utilize proprietary synthetic peptides that mimic the mechanism of cell attachment to fibrin. These peptides have demonstrated the ability to significantly enhance cell attraction and attachment providing the potential to use Haptides™ in the development of product opportunities applicable to the cosmetic tissue augmentation, wound healing, orthopedics, and drug delivery markets.

[MWM]

Corporate Overview Features


Founded in 1991 to develop a tissue- engineered product now known as OrCel®

Publicly traded company since 1996

Raised nearly $150 million to fund R&D

Fully integrated organization -- approximately 40 employees

FDA approved cGMP

FDA approved cGMP pilot manufacturing facility

Initial focus on treatment of acute and chronic wounds - granted two FDA product approvals for non-cryopreserved OrCel®

[MWM]

http://www.forticellbioscience.com/

[OTC BB King]

Only 13M O/S, could bounce bigly IMO. On watch.

[aquaspin]

Nothing but buys at the .035 ask today.

[J-RO]

FORB on watch ~

[MWM]

never know, one to keep an eye on for sure...

[aquaspin]

What do you think is possible with this one? Instead of rejecting the product, can the FDA just request more time/information? If so, then that kind of news could give this a little run.

[MWM]

Nice bottom here...